Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Klaus H. Metzeler, MD, Maja Rothenberg-Thurley, PhD, Dennis Görlich, PhD, Maria Cristina Sauerland, Annika Maria Dufour, PhD, Stephanie Schneider, PhD, Marion Subklewe, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, Prof., MD, Utz Krug, MD, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, MD, Tobias Herold, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-137487

Published: 2020

Journal Articles

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

Christina Maria Zeller, MSc, Daniel Richter, MSc, Binje Vick, PhD, Tobias Herold, MD, Johannes Bagnoli, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Karsten Spiekermann, MD, Wolfgang Enard, PhD, Irmela Jeremias, MD PhD

Blood (2019) 134 (Supplement_1): 1450.

https://doi.org/10.1182/blood-2019-127867

Published: 2019

Journal Articles

NPM1 Variant Allele Frequency and Outcomes in AML

Blood (2018) 132 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2018-99-112549

Published: 2018

Journal Articles

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Sophie M. Stief, M.Sc., Anna-Li Hanneforth, Raphael Mattes, Sabrina Weser, M.Sc., Binje Vick, PhD, Michael D. Bartoschek, M.Sc., Helena Domínguez Moreno, M.Sc., Wen-Hsin Liu, PhD, Bianka Ksienzyk, Maja Rothenberg-Thurley, PhD, Hilmar Quentmeier, PhD, Wolfgang Hiddemann, Klaus H. Metzeler, MD, Gunnar Schotta, PhD, Sebastian Bultmann, PhD, Irmela Jeremias, MD PhD, Heinrich Leonhardt, PhD, Karsten Spiekermann, MD

Blood (2018) 132 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2018-99-114959

Published: 2018

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

Veit Bücklein, MD, Thomas Koehnke, MD, Sandra Rechkemmer, Frauke Schnorfeil, PhD, Stephanie Schneider, PhD, Maja Rothenberg-Thurley, PhD, Klaus H. Metzeler, MD, Cristina Sauerland, Wolfgang Hiddemann, MD PhD, Karsten Spiekermann, Marion S. Subklewe, MD

Blood (2017) 130 (Supplement 1): 5081.

https://doi.org/10.1182/blood.V130.Suppl_1.5081.5081

Published: 2017

Journal Articles

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

Blood (2016) 128 (22): 1209.

https://doi.org/10.1182/blood.V128.22.1209.1209

Published: 2016

Journal Articles

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Blood (2015) 126 (23): 3815.

https://doi.org/10.1182/blood.V126.23.3815.3815

Published: 2015

Journal Articles

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Maja Rothenberg-Thurley, PhD, Stephanie Schneider, Dr. rer. nat., Tobias Herold, MD, Nikola P Konstandin, Annika Dufour, PhD, Kathrin Bräundl, Bianka Ksienzyk, Evelyn Zellmeier, Philipp A Greif, MD, Michael Fiegl, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Wolfgang Hiddemann, MD, Jan Braess, MD, Karsten Spiekermann, MD, Klaus H. Metzeler, MD

Blood (2014) 124 (21): 697.

https://doi.org/10.1182/blood.V124.21.697.697

Published: 2014

NARROW

PTPN11 mutations and Outcomes in Adult Patients with Acute Myeloid Leukemia

Single Cell Clones Derived from a Patient's AML Xenograft Display Genetic and Functional Heterogeneity

NPM1 Variant Allele Frequency and Outcomes in AML

Loss of KDM6A Confers Drug Resistance in Acute Myeloid Leukemia

Minimal Residual Disease (MRD) Detection By Flow Cytometry during Aplasia and Post-Induction Is an Independent Prognostic Parameter for Relapse-Free Survival in AML

PS29MRC - a Novel Predictive Score for Response to Therapy in Acute Myeloid Leukemia

DNMT3A Mutations Associate with Shorter Survival and Modulate the Prognostic Impact of Mutated NPM1: an Analysis Based on Comprehensive Mutational Screening of 660 AML Patients Treated on German AML Cooperative Group (AMLCG) Trials

Targeted, Deep Sequencing of Adult AML Patients Treated on the AMLCG-2008 Trial Detects Clonal Heterogeneity in 52% of Patients at Initial Diagnosis and Reveals Patterns of Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only